149 related articles for article (PubMed ID: 27663271)
21. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
[TBL] [Abstract][Full Text] [Related]
22. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.
Lucar O; Sadjo Diallo M; Bayard C; Samri A; Tarantino N; Debré P; Thiébaut R; Brun-Vézinet F; Matheron S; Cheynier R; Vieillard V;
AIDS; 2019 Jan; 33(1):23-32. PubMed ID: 30325780
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
24. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling.
Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H
Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site.
Joyce MG; Tran P; Zhuravleva MA; Jaw J; Colonna M; Sun PD
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6223-8. PubMed ID: 21444796
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract][Full Text] [Related]
27. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
[TBL] [Abstract][Full Text] [Related]
28. Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.
Salimi M; Xue L; Jolin H; Hardman C; Cousins DJ; McKenzie AN; Ogg GS
J Immunol; 2016 Jan; 196(1):45-54. PubMed ID: 26582946
[TBL] [Abstract][Full Text] [Related]
29. The B7 Family Member B7-H6: a New Bane of Tumor.
Chen Y; Mo J; Jia X; He Y
Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
[TBL] [Abstract][Full Text] [Related]
30. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
[TBL] [Abstract][Full Text] [Related]
31.
Liu X; Guo R; Xu Y
Genet Test Mol Biomarkers; 2021 Jul; 25(7):463-470. PubMed ID: 34280008
[No Abstract] [Full Text] [Related]
32. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
[TBL] [Abstract][Full Text] [Related]
33. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
Phillips M; Romeo F; Bitsaktsis C; Sabatino D
Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
[TBL] [Abstract][Full Text] [Related]
34. Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.
Mantovani S; Oliviero B; Lombardi A; Varchetta S; Mele D; Sangiovanni A; Rossi G; Donadon M; Torzilli G; Soldani C; Porta C; Pedrazzoli P; Chiellino S; Santambrogio R; Opocher E; Maestri M; Bernuzzi S; Rossello A; Clément S; De Vito C; Rubbia-Brandt L; Negro F; Mondelli MU
Hepatology; 2019 Mar; 69(3):1165-1179. PubMed ID: 30153337
[TBL] [Abstract][Full Text] [Related]
35. The potential of B7-H6 as a therapeutic target in cancer immunotherapy.
Mohammadi A; Najafi S; Amini M; Mansoori B; Baghbanzadeh A; Hoheisel JD; Baradaran B
Life Sci; 2022 Sep; 304():120709. PubMed ID: 35697295
[TBL] [Abstract][Full Text] [Related]
36. Dual role of B7-H6 as a novel prognostic marker in hepatocellular carcinoma.
Qiu H; Gao S; Sun Z; Wang J
APMIS; 2021 Mar; 129(3):105-117. PubMed ID: 33220098
[TBL] [Abstract][Full Text] [Related]
37. B7-H6 expression in non-small cell lung cancers.
Zhang X; Zhang G; Qin Y; Bai R; Huang J
Int J Clin Exp Pathol; 2014; 7(10):6936-42. PubMed ID: 25400778
[TBL] [Abstract][Full Text] [Related]
38. Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its
Skořepa O; Pazicky S; Kalousková B; Bláha J; Abreu C; Ječmen T; Rosůlek M; Fish A; Sedivy A; Harlos K; Dohnálek J; Skálová T; Vaněk O
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708305
[TBL] [Abstract][Full Text] [Related]
39. B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines.
Bjørnsen EG; Thiruchelvam-Kyle L; Hoelsbrekken SE; Henden C; Saether PC; Boysen P; Daws MR; Dissen E
Eur J Immunol; 2019 Jan; 49(1):54-65. PubMed ID: 30512185
[TBL] [Abstract][Full Text] [Related]
40. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
